Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 5/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5232665 | 0.87 | TSHR (0.38) | TSHRPTK2BSMN1; SMN2ADORA3ACHE | |
| SCHEMBL5239426 | 0.86 | TSHR (0.39) | TSHRPTK2BRAB9ASMN1; SMN2LMNA | |
| SCHEMBL5237163 | 0.86 | DPP4 (0.48) | PRMT5WDR77TSHRPTK2BRAB9A | |
| SCHEMBL5234959 | 0.85 | PRMT5 (0.39) | MAPK8PRMT5WDR77TSHRPTK2B | |
| SCHEMBL5239965 | 0.84 | MAPK8 (0.44) | MAPK8DPP4SMN1; SMN2LMNAADORA3 | |
| SCHEMBL5239784 | 0.84 | MAPK8 (0.53) | MAPK8DPP4SMN1; SMN2LMNAACHE | |
| SCHEMBL5234694 | 0.79 | MAPK8 (0.45) | MAPK8SMN1; SMN2LMNA | |
| SCHEMBL5235048 | 0.77 | MAPK8 (0.55) | MAPK8SMN1; SMN2LMNA | |
| SCHEMBL5239586 | 0.76 | SMN1; SMN2 (0.48) | TSHRPTK2BDPP4SMN1; SMN2LMNA | |
| SCHEMBL6109713 | 0.76 | MAPK8 (0.42) | MAPK8DPP4SMN1; SMN2LMNAACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355886-B1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-7034039-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-25 | — | — | US | disclosed |
| US-20040082607-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082607-A1 | Fused heterocyclic compounds | DPP7, DPP4, METAP1 | MAPK8 2612/4885PRMT5 176/4885WDR77 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.